Allergy & Immunotherapy : Rules for Pilots

FAA Policies on Pharmaceuticals for Airmen

Apr 2014

Guidance is compiled and interpreted by professional pilots and physicians at FlightPhysical.com from the 2014 AME Guide, FAA and FDA web data (www.FAA.gov & www.FDA.gov), instructions specified in the Aeronautical Information Manual, Federal Air Surgeon Bulletins from 1999-2015, and 14 CFR Part 61 and Part 67 (the FARs).

Code of Federal Regulations for Airmen
- First-Class Airman Medical Certificate: 67.105(b)(c)
- Second-Class Airman Medical Certificate: 67.205(b)(c)
- Third-Class Airman Medical Certificate: 67.305(b)(c)
Medical History: See Item 18.e., Hay fever or allergy.
The applicant should report frequency and duration of symptoms, any incapacitation by the condition, treatment, and side effects. The AME should inquire whether the applicant has ever experienced any barotitis (ear block), barosinusitis, alternobaric vertigo, or any other symptoms that could interfere with aviation safety.
Aeromedical Decision Considerations:
- See Item 26, Nose, Aerospace Medical Disposition table
- Also see Aerospace Medical Disposition table and Item 35, Lungs and Chest
Protocol:
See Disease Protocols - Allergies, Severe .
Pharmaceutical Considerations:
- For conditions controlled by desensitization, AME must warn the airman to not operate aircraft until four hours after each injection.
- Sublingual immunotherapy (SLIT) used for allergic rhinitis is not acceptable.

Summary: This page reviewed the medical and legal aviation aspects of Allergy & Immunotherapy compiled from recent FAA and FDA reports.

This page discussed Allergy & Immunotherapy : Rules for Pilots

Reminder: use FlightPhysical.com to familiarize yourself with aviation medical regulations and guidelines, but always discuss your specific situation with one or more AMEs before dedicating resources toward expensive clinical workups. Find an AME now